BRIEF-PharmAla Biotech Executes Definitive License Agreement Granting Jupiter Neurosciences Exclusive US Rights To Ala-002

Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS

0.00

July 21 (Reuters) - Jupiter Neurosciences Inc JUNS.O:

  • PHARMALA BIOTECH EXECUTES DEFINITIVE LICENSE AGREEMENT GRANTING JUPITER NEUROSCIENCES EXCLUSIVE U.S. RIGHTS TO ALA-002

  • PHARMALA BIOTECH - DEAL VALUED UP TO $100 MILLION INCLUDING $3.33 MILLION UPFRONT AND MILESTONES PLUS ROYALTIES

  • PHARMALA BIOTECH - UPFRONT PAYMENT OF $3.33 MILLION: $1.50 MILLION CASH, $1.83 MILLION IN JUPITER STOCK

  • PHARMALA BIOTECH - DEVELOPMENT AND REGULATORY MILESTONES UP TO $23.33 MILLION INCLUDING $20 MILLION FOR FDA APPROVAL

  • PHARMALA BIOTECH - COMMERCIALIZATION MILESTONES UP TO $73.33 MILLION BASED ON U.S. NET SALES TARGETS

  • PHARMALA BIOTECH - TO RECEIVE 3% ROYALTY ON U.S. NET SALES AFTER THIRD MILESTONE

  • PHARMALA BIOTECH - TO MANUFACTURE GMP-GRADE ALA-002 FOR JUPITER UNDER SEPARATE SUPPLY AGREEMENT

Source text: ID:nGNXb746NG

Further company coverage: JUNS.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.